Your browser doesn't support javascript.
loading
Management of Lung Cancer in the Patient with Interstitial Lung Disease.
Frank, Angela J; Dagogo-Jack, Ibiayi; Dobre, Ioana A; Tait, Sarah; Schumacher, Lana; Fintelmann, Florian J; Fingerman, Leah M; Keane, Florence K; Montesi, Sydney B.
Afiliación
  • Frank AJ; Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA, USA.
  • Dagogo-Jack I; Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, MA, USA.
  • Dobre IA; Queen's University School of Medicine, Kingston, ON, Canada.
  • Tait S; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
  • Schumacher L; Department of Surgery, Massachusetts General Hospital, Boston, MA, USA.
  • Fintelmann FJ; Department of Radiology, Division of Thoracic Imaging and Intervention, Massachusetts General Hospital, Boston, MA, USA.
  • Fingerman LM; Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA, USA.
  • Keane FK; Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA.
  • Montesi SB; Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA, USA.
Oncologist ; 28(1): 12-22, 2023 01 18.
Article en En | MEDLINE | ID: mdl-36426803
Patients with interstitial lung disease (ILD), especially those with pulmonary fibrosis, are at increased risk of developing lung cancer. Management of lung cancer in patients with ILD is particularly challenging. Diagnosis can be complicated by difficulty differentiating lung nodules from areas of focal fibrosis, and percutaneous biopsy approaches confer an increased risk of complications in those with pulmonary fibrosis. Lung cancer treatment in these patients pose several specific considerations. The degree of lung function impairment may preclude lobectomy or surgical resection of any type. Surgical resection can trigger an acute exacerbation of the underlying ILD. The presence of ILD confers an increased risk of pneumonitis with radiotherapy, and many of the systemic therapies also carry an increased risk of pneumonitis in this population. The safety of immunotherapy in the setting of ILD remains to be fully elucidated and concerns remain as to triggering pneumonitis. The purpose of this review is to summarize the evidence regarding consideration for tissue diagnosis, chemotherapy and immunotherapy, radiotherapy, and surgery, in this patient population and discuss emerging areas of research. We also propose a multidisciplinary approach and practical considerations for monitoring for ILD progression during lung cancer treatment.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neumonía / Fibrosis Pulmonar / Enfermedades Pulmonares Intersticiales / Neoplasias Pulmonares Límite: Humans Idioma: En Revista: Oncologist Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neumonía / Fibrosis Pulmonar / Enfermedades Pulmonares Intersticiales / Neoplasias Pulmonares Límite: Humans Idioma: En Revista: Oncologist Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido